Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements review uncovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/C